Literature DB >> 11564593

Immune dysfunction and immune restoration disease in HIV patients given highly active antiretroviral therapy.

P Price1, N Mathiot, R Krueger, S Stone, N M Keane, M A French.   

Abstract

BACKGROUND: Some immune defects caused by HIV infection resolve following treatment with highly active antiretroviral therapy (HAART), but residual immune dysfunction may cause disease. Problems with the regulation of the restored immune system in the first six months of treatment can lead to atypical presentations of mycobacterial, cytomegalovirus (CMV), hepatitis B virus or hepatitis C virus (HCV) disease. We defined these conditions as immune restoration diseases (IRD) and showed that they occur in 30-40% of individuals who begin HAART from low CD4 T cell counts.
OBJECTIVES: Analysis of immune dysregulation in patients who have responded to HAART. STUDY
DESIGN: Patients with successful immune reconstitution following HAART were selected from a database containing details of all patients managed at Royal Perth Hospital (Western Australia) on the basis a CD4 T cell count <100/microl before HAART and an increase of >4-fold or to >200 CD4 T cells/microl.
RESULTS: Patients who had experienced an IRD demonstrated increased levels of bioavailable IL-6 and increased expression of CCR5 and CCR3 on monocytes and granulocytes, but numbers of gammadeltaT-cells were similar to patients with similar CD4 T cell counts without an IRD. Carriage of HLA-A2, -B44 was associated with a history of CMV retinitis and/or encephalomyelitis as an IRD, but not with IRD initiated by Mycobacterium sp., cutaneous varicella zoster or herpes simplex infections or HCV. We also identified a patient with Graves' thyrotoxicosis and pronounced lymphadenopathy after HAART, and demonstrated that thyroid stimulating hormone receptor antibody production was associated with an increase in serum soluble CD30, suggesting acquired immune dysregulation.
CONCLUSIONS: IRD are associated with persistent immune activation, where differences in genetic profiles suggest that distinct pathological mechanisms are responsible for retinitis/encephalomyelitis IRD. Further studies are important as dysregulated T-cell responses may cause disease later in the course of immune reconstitution.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11564593     DOI: 10.1016/s1386-6532(01)00200-1

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  23 in total

Review 1.  Immune reconstitution inflammatory syndrome-associated Burkitt lymphoma after combination antiretroviral therapy in HIV-infected patients.

Authors:  Prakash Vishnu; Russell P Dorer; David M Aboulafia
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2014-10-02

2.  Role of IL-6 in Mycobacterium avium--associated immune reconstitution inflammatory syndrome.

Authors:  Daniel L Barber; Bruno B Andrade; Cortez McBerry; Irini Sereti; Alan Sher
Journal:  J Immunol       Date:  2013-12-11       Impact factor: 5.422

Review 3.  Immune restoration inflammatory syndromes: apparently paradoxical clinical events after the initiation of HAART.

Authors:  Matthias Stoll; Reinhold E Schmidt
Journal:  Curr HIV/AIDS Rep       Date:  2004-09       Impact factor: 5.071

Review 4.  An official ATS workshop report: Emerging issues and current controversies in HIV-associated pulmonary diseases.

Authors:  Alison Morris; Kristina Crothers; James M Beck; Laurence Huang
Journal:  Proc Am Thorac Soc       Date:  2011-03

Review 5.  Pathogenesis and prevention of immune reconstitution disease during antiretroviral therapy.

Authors:  Stephen D Lawn; Graeme Meintjes
Journal:  Expert Rev Anti Infect Ther       Date:  2011-04       Impact factor: 5.091

6.  Liver transplantation in HCV/HIV positive patients.

Authors:  Yasuhiko Sugawara; Sumihito Tamura; Norihiro Kokudo
Journal:  World J Gastrointest Surg       Date:  2011-02-27

Review 7.  [Immune restoration inflammatory syndromes].

Authors:  M Stoll; H Heiken; G M N Behrens; R E Schmidt
Journal:  Internist (Berl)       Date:  2004-08       Impact factor: 0.743

8.  Immune Restoration Inflammatory Syndromes: The Dark Side of Successful Antiretroviral Treatment.

Authors:  Matthias Stoll; Reinhold E. Schmidt
Journal:  Curr Infect Dis Rep       Date:  2003-06       Impact factor: 3.725

9.  Integration and co-location of HIV/AIDS, tuberculosis and drug treatment services.

Authors:  Laurie Sylla; R Douglas Bruce; Adeeba Kamarulzaman; Frederick L Altice
Journal:  Int J Drug Policy       Date:  2007-05-10

10.  The effect of human immunodeficiency virus-1 on monocyte-derived dendritic cell maturation and function.

Authors:  P Fairman; J B Angel
Journal:  Clin Exp Immunol       Date:  2012-10       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.